drugset / Trial / NCT07413939
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Timeline
- Start
- 2026-05-21
- Primary completion
- 2029-05-01
- Completion
- 2032-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tucatinib | Small molecule | — | Oral |
| Subject | ZN-A-1041 | Unknown | — | Oral |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Trastuzumab | Monoclonal antibody | — | Intravenous |